[go: up one dir, main page]

MX2018004286A - Metodos de tratamiento de lesiones o condiciones relacionadas con el edema del sistema nervioso central. - Google Patents

Metodos de tratamiento de lesiones o condiciones relacionadas con el edema del sistema nervioso central.

Info

Publication number
MX2018004286A
MX2018004286A MX2018004286A MX2018004286A MX2018004286A MX 2018004286 A MX2018004286 A MX 2018004286A MX 2018004286 A MX2018004286 A MX 2018004286A MX 2018004286 A MX2018004286 A MX 2018004286A MX 2018004286 A MX2018004286 A MX 2018004286A
Authority
MX
Mexico
Prior art keywords
conditions related
edema
treatment
reducing
methods
Prior art date
Application number
MX2018004286A
Other languages
English (en)
Other versions
MX392466B (es
Inventor
Martin Jacobson Sven
Original Assignee
Biogen Chesapeake Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Chesapeake Llc filed Critical Biogen Chesapeake Llc
Publication of MX2018004286A publication Critical patent/MX2018004286A/es
Publication of MX392466B publication Critical patent/MX392466B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente tecnología está relacionada con la reducción o el tratamiento del hinchamiento neurológico y condiciones relacionadas con los inhibidores de los canales de SUR1-TRPM4; en algunas modalidades, los métodos incluyen: reducir el deterioro neurológico tardío o prevenir la muerte, reducir el desplazamiento de la línea media cerebral, reducir el grado de discapacidad en un sujeto, contrarrestar los niveles de glucosa en sangre en un sujeto que recibe un inhibidor de los canales de SUR1-TRPM4, prevenir el edema cerebral, monitorear la actividad de las enzimas del hígado junto con el tratamiento de las lesiones o condiciones relacionadas con el edema del SNC, o monitorear la actividad cardiaca junto con el tratamiento de las lesiones o condiciones relacionadas con el edema del SNC.
MX2018004286A 2015-10-07 2016-10-07 Metodos de tratamiento de lesiones o condiciones relacionadas con el edema del sistema nervioso central MX392466B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562238461P 2015-10-07 2015-10-07
PCT/US2016/055988 WO2017062765A1 (en) 2015-10-07 2016-10-07 Methods of treating injuries or conditions related to cns edema

Publications (2)

Publication Number Publication Date
MX2018004286A true MX2018004286A (es) 2018-08-09
MX392466B MX392466B (es) 2025-03-24

Family

ID=58488580

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004286A MX392466B (es) 2015-10-07 2016-10-07 Metodos de tratamiento de lesiones o condiciones relacionadas con el edema del sistema nervioso central

Country Status (15)

Country Link
US (4) US20180280325A1 (es)
EP (1) EP3359162B1 (es)
JP (3) JP7349786B2 (es)
KR (2) KR102681027B1 (es)
CN (2) CN115737816A (es)
AU (3) AU2016335767B2 (es)
BR (1) BR112018006925A2 (es)
CA (1) CA3001321A1 (es)
EA (1) EA201890893A1 (es)
ES (1) ES2940669T3 (es)
HK (1) HK1257542A1 (es)
IL (1) IL258509B2 (es)
MA (1) MA45574A (es)
MX (1) MX392466B (es)
WO (1) WO2017062765A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102200176B1 (ko) 2012-05-08 2021-01-11 에어로믹스, 인코포레이티드 신규 방법
MX386250B (es) 2013-11-06 2025-03-18 Aeromics Inc Formulaciones novedosas.
WO2020041905A1 (en) * 2018-08-31 2020-03-05 The University Of British Columbia Methods for identifying compounds suitable for treatment of central nervous system trauma and uses of those compounds
MA55813A (fr) * 2019-05-02 2022-03-09 Biogen Chesapeake Llc Procédé de traitement de sujets souffrant de contusions du système nerveux central
US12492166B2 (en) * 2020-07-17 2025-12-09 Shanghai Senhui Medicine Co., Ltd Sulfonylurea derivative and medical uses thereof
WO2025212155A1 (en) * 2024-04-05 2025-10-09 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke with large vessel occlusion using a sur1-trpm4 channel inhibitor
WO2025212189A1 (en) * 2024-04-05 2025-10-09 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema using a sur1-trpm4 channel inhibitor
WO2025212154A1 (en) * 2024-04-05 2025-10-09 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
US12251389B1 (en) 2024-04-22 2025-03-18 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
US12251388B1 (en) 2024-05-09 2025-03-18 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856360A (en) 1996-05-03 1999-01-05 Children's Hospital Medical Center Pharmaceutical method for the treatment of severe blood loss and for the inhibition or treatment of hemorrhagic shock
US8980952B2 (en) * 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
EP1529058B1 (en) 2002-03-20 2013-11-06 University of Maryland Baltimore A non-selective cation channel in neural cells and sur1 antagonists for treating brain swelling
US20050246000A1 (en) * 2004-05-03 2005-11-03 Seacoast Technologies, Inc. Cooled craniectomy
CA3065983C (en) 2007-06-22 2022-07-26 The United States Of America As Represented By The Department Of Veterans Affairs Inhibitors of ncca-atp channels for therapy
CA2707484C (en) * 2007-12-04 2021-08-10 Remedy Pharmaceuticals, Inc. Improved formulations and methods for lyophilization and lyophilates provided thereby
KR20200054319A (ko) 2010-07-19 2020-05-19 바이오젠 체사피크 엘엘씨 글리부리드 및 다른 약물의 정맥내 투여를 위한 방법

Also Published As

Publication number Publication date
EA201890893A1 (ru) 2018-09-28
MA45574A (fr) 2019-05-15
JP2018530564A (ja) 2018-10-18
US20180280325A1 (en) 2018-10-04
JP2023053274A (ja) 2023-04-12
EP3359162B1 (en) 2022-12-21
JP7592768B2 (ja) 2024-12-02
IL258509B (en) 2022-12-01
AU2022279369B2 (en) 2025-02-13
AU2016335767A1 (en) 2018-05-24
KR20180063296A (ko) 2018-06-11
WO2017062765A1 (en) 2017-04-13
IL258509A (en) 2018-05-31
US20240216309A1 (en) 2024-07-04
BR112018006925A2 (pt) 2018-10-16
ES2940669T3 (es) 2023-05-10
AU2025202620A1 (en) 2025-05-01
US20220125750A1 (en) 2022-04-28
KR102681027B1 (ko) 2024-07-02
JP7349786B2 (ja) 2023-09-25
EP3359162A1 (en) 2018-08-15
AU2022279369A1 (en) 2023-01-19
EP3359162A4 (en) 2019-08-28
CA3001321A1 (en) 2017-04-13
CN115737816A (zh) 2023-03-07
JP2024164167A (ja) 2024-11-26
JP2021073317A (ja) 2021-05-13
IL258509B2 (en) 2023-04-01
KR20240105519A (ko) 2024-07-05
AU2016335767B2 (en) 2022-10-06
AU2016335767A8 (en) 2018-06-28
MX392466B (es) 2025-03-24
US11951085B2 (en) 2024-04-09
CN108348534A (zh) 2018-07-31
US20250017880A1 (en) 2025-01-16
HK1257542A1 (zh) 2019-10-25

Similar Documents

Publication Publication Date Title
MX2018004286A (es) Metodos de tratamiento de lesiones o condiciones relacionadas con el edema del sistema nervioso central.
NI201900019A (es) Inhibidores de procesos metabólicos celulares
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
MX2021013974A (es) Metodos, sistemas y dispositivos de seleccion de pacientes tl1a.
MX2023001527A (es) Compuestos con actividad inductora de ferroptosis y metodos de uso de estos.
EP4272757A3 (en) Modified nk-92 cells for treating cancer
CO2017011197A2 (es) Terapia de combinación fgfr/pd-1 para el tratamiento del cancer
MX2019002750A (es) Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer.
ECSP23007180A (es) Compuestos tricíclicos de urea como inhibidores de jak2 v617f
PH12021551455A1 (en) Jak1 pathway inhibitors for the treatment of gastrointestinal disease
MX381260B (es) Inhibidores heterociclicos de glutaminasa.
WO2015117032A8 (en) Treatment systems and methods for affecting glands and other targeted structures
EA201500996A1 (ru) Терапевтические применения эмпаглифлозина
MX2020011481A (es) Dispositivo de fijacion que tiene una correa y vendaje integral.
MX2014006904A (es) Método y sistema para determinar la regularidad asociada a los trastornos del ritmo biológico.
MX2021010173A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso.
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
MX2024006769A (es) Compuestos y usos de los mismos.
MX2015012444A (es) Metodos de diagnostico, seleccion y tratamiento de enfermedades y afecciones provocadas por o asociadas con metanogenos.
MX387658B (es) Métodos para tratar y/o prevenir queratosis actínica.
WO2021041539A3 (en) Pyrido-indole analogues as gpx4 inhibitors
CL2024002772A1 (es) Compuestos de urea triciclicos como inhibidores de jak2 v617f.
JOP20190112A1 (ar) علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي
GB201202561D0 (en) Treatment of skin disorders